Market closedNon-fractional
Rallybio/RLYB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Rallybio
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Ticker
RLYB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New Haven, United States
Employees
30
Website
www.rallybio.com
Rallybio Metrics
BasicAdvanced
$55M
Market cap
-
P/E ratio
-$1.88
EPS
-1.63
Beta
-
Dividend rate
Price and volume
Market cap
$55M
Beta
-1.63
Financial strength
Current ratio
9.77
Quick ratio
9.337
Long term debt to equity
0.13
Total debt to equity
0.38
Management effectiveness
Return on assets (TTM)
-36.80%
Return on equity (TTM)
-62.43%
Valuation
Price to book
0.57
Price to tangible book (TTM)
0.57
Price to free cash flow (TTM)
-0.947
Growth
Earnings per share change (TTM)
-7.19%
3-year earnings per share growth
5.61%
What the Analysts think about Rallybio
Analyst Ratings
Majority rating from 6 analysts.
Rallybio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$19M
-5.94%
Profit margin
0.00%
NaN%
Rallybio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.46
-$0.45
-$0.50
-$0.47
-
Expected
-$0.48
-$0.51
-$0.45
-$0.47
-$0.37
Surprise
-3.74%
-11.52%
11.23%
-0.84%
-
Rallybio News
AllArticlesVideos
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
Business Wire·3 weeks ago
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
Business Wire·3 months ago
Rallybio partners with J&J to advance therapies targeting rare fetal disease
Proactive Investors·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rallybio stock?
Rallybio (RLYB) has a market cap of $55M as of July 06, 2024.
What is the P/E ratio for Rallybio stock?
The price to earnings (P/E) ratio for Rallybio (RLYB) stock is 0 as of July 06, 2024.
Does Rallybio stock pay dividends?
No, Rallybio (RLYB) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Rallybio dividend payment date?
Rallybio (RLYB) stock does not pay dividends to its shareholders.
What is the beta indicator for Rallybio?
Rallybio (RLYB) has a beta rating of -1.63. This means that it has an inverse relation to market volatility.
Buy or sell Rallybio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.